The positive inotropic effect of the j-adrenoceptor agonist isoproterenol is accompanied by inhibition of phosphatase type 1 activity in myocardium. Indirect assays suggest that this effect is due to activation of protein phosphatase inhibitor-1, which inhibits phosphatase activity only when phosphorylated. To hanced by a positive feedback system wherein a regulatory protein, when phosphorylated by protein kinase A, can inhibit the activity of type 1 protein phosphatase.5-7This regulatory protein, termed inhibitor-1, is active only when phosphorylated.7 As phosphatases counteract the phosphorylation of proteins induced by protein kinase A, inhibition of phosphatases would indirectly enhance and prolong the phosphorylated state of proteins and hence potentiate the effects of cAMP-increasing agents. Recently, it has been reported that isoproterenol increases the activity of inhibitor-1 in perfused hearts.56 However, it has not been directly demonstrated that these changes in activity are accompanied by phosphorylation of inhibitor-1. In addition, some investigators have suggested that inhibitor-1 does not even exist in cardiac tissue.3
C atecholamines such as isoproterenol lead to activation of adenylate cyclase and hence to generation of cAMP via occupation of ,B-adrenergic receptors.1 As a result of increased levels of cAMP, protein kinase A is activated and it phosphorylates a variety of regulatory proteins.23 Phosphorylation of these proteins leads to the inotropic, electrophysiological, and metabolic effects of catecholamines in cardiac tissue.2-4 Recent studies suggest that protein kinase A-induced phosphorylation can be en-hanced by a positive feedback system wherein a regulatory protein, when phosphorylated by protein kinase A, can inhibit the activity of type 1 protein phosphatase.5-7This regulatory protein, termed inhibitor-1, is active only when phosphorylated.7 As phosphatases counteract the phosphorylation of proteins induced by protein kinase A, inhibition of phosphatases would indirectly enhance and prolong the phosphorylated state of proteins and hence potentiate the effects of cAMP-increasing agents.
Recently, it has been reported that isoproterenol increases the activity of inhibitor-1 in perfused hearts.56 However, it has not been directly demonstrated that these changes in activity are accompanied by phosphorylation of inhibitor-1. In addition, some investigators have suggested that inhibitor-1 does not even exist in cardiac tissue.3
In the present study it is demonstrated that a protein of about 26 kd molecular mass is phosphorylated in vivo in response to isoproterenol. This protein reacts with an antibody raised against skeletal muscle inhibitor-1.
Materials and Methods

Heart Perfusion
Hearts were obtained from guinea pigs of either sex weighing 350-450 g and perfused by the Langendorff technique as previously described. 8 The composition of the oxygenated (95% 02-5% C02) Krebs-Henseleit buffer was (milliosmolarity) NaHCO3 27.2, NaCI 118, KCl 4.8, KH2PO4 0.23, MgSO4 1.2, CaCI2 2.5, and glucose 11.1. The pH of the buffer was maintained at 7.4 at 30°C. The diastolic tension was adjusted to 5 g, and the hearts were continuously stimulated at a rate of 3 Hz. After 10 minutes of perfusion by drip-through at a constant rate of 6.0 ml/min, the perfusion circuit was switched to a recirculating system containing 60 ml of the same buffer to which 2.0 mCi of 32p; was added. After 30 minutes of perfusion with the radioactive buffer, the hearts were returned to nonrecirculating perfusion with nonradioactive buffer, after which drugs were administered by continuous infusion. After 1 minute, the hearts were freeze-clamped with clamps cooled in liquid nitrogen, pulverized in a precooled mortar and pestle, and stored under liquid nitrogen until further analysis. Nonradioactive hearts were perfused in the same way, but the labeling perfusion period was omitted.
Isolation of Inhibitor-I
Inhibitor-1 was isolated from 32P-labeled and nonradioactive heart in the same way as published previously. 6 In brief, about 500 mg powdered tissue was simultaneously thawed and homogenized in 5 ml ice-cold 1.5% trichloroacetic acid containing 4 mM EDTA by using a polytron three times for 30 seconds each. Extracts were dephosphorylated by type 2 phosphatase from rabbit skeletal muscle. The 20 ,l of reaction mixture contained 10 pl extract, 5 mmol MnCl2, and type 2 protein phosphatase. The reaction was performed at 30°C for 60 minutes and was terminated by boiling for 5 minutes. An aliquot was used for the assay of inhibitor-1 activity. Inhibitor activity in extracts was measured using type 1 protein phosphatase from rabbit skeletal muscle.
Back-Phosphorylation of Inhibitor-i
Inhibitor-1-enriched fractions from perfused hearts were in vitro phosphorylated as described above but with [y-32P]ATP instead of nonradioactive ATP. Samples were subjected to electrophoresis.
Acrylamide Gel Electrophoresis
Lyophilized inhibitor-l-enriched fractions from radioactively labeled hearts were resuspended in electrophoresis buffer, and an aliquot was solubilized by adding an equal volume of a sample buffer containing 12% (wt/vol) sodium dodecyl sulfate, 62.5 mM Tris-HCI (pH 6.8), 20% glycerol, and 40 mM dithiothreitol with 0.001% bromphenol blue. Electrophoresis were performed in 10% polyacrylamide gels according to the method of Laemmli.9 Protein (5-75 ,g) was applied to each lane as indicated in the legends to the figures. The gels were then fixed, stained, and dried as described.
Autoradiography was performed by placing the dried gels in Lanex regular cassettes (Kodak, Rochester, N.Y.) with Cronex 4 film (E.I. Dupont de Nemours & Co., Wilmington, Del.) with exposures for 24-48 hours at -700C. The radioactive bands corresponding to the autoradiogram were cut from the dried gels, and 32P incorporation was determined by liquid scintillation counting. Phosphate incorporation was quantitated by dividing the 32P incorporation by the specific activity of [y-32P]ATP determined for that heart.
Antibody Methods
Samples were subjected to electrophoresis. Separated proteins were electrophoretically transferred to nitrocellulose in 50 mM sodium phosphate buffer (pH 7.5). Transfer time was 1 hour at 1.6 A.10 Nitrocellulose sheets of radioactive samples were exposed in cassettes as described above. After autoradiograms were obtained, nitrocellulose was incubated with antiserum (raised as previously described'1) from rabbit against skeletal muscle inhibitor-1 at 1:133 dilution. Proteins binding antiserum were visualized colorimetrically with the use of alkaline phosphatase-conjugated goat anti-rabbit immunoglobulin G diluted 1:5,000.
Immunoprecipitation
Radioactive fractions enriched in inhibitor-1 were prepared as described above. Fractions of 60 ,ul (130 ,ug protein) were diluted in 60 ,gl TBS (50 mM Tris HCl, 150 mM NaCl, pH 7.4) and divided into two parts. One part was kept for electrophoresis. To the other part, 20 ,ul of anti-inhibitor-1 antiserum was added. In some experiments (see Figure 5 ) the antiserum was preincubated for 1 hour with 1 ,g pure skeletal muscle inhibitor-1. This mixture was incubated at 4°C for 60 minutes. Then 50 ,l of 10% (wt/vol) formalin-fixed protein A-bearing Staphylococcus aureus cells (SAC) was added for 60 minutes at 4°C. The SAC was removed by centrifugation in a Fisher Model 205 centrifuge for 1 minute at maximal speed. The supernatant was removed and the pellet resuspended in 100 ,ul TBS and again centrifuged. This procedure was repeated two times. The final pellet was resuspended in 100 ,ul Laemmli sample buffer and boiled for 5 minutes before it was subjected to electrophoresis and autoradiography.
Miscellaneous Methods
The specific activity of [-y-2P]ATP in small samples of each heart was determined as previously de inhibitor-1 in a concentration-dependent manner. Extracts from nonradioactively perfused hearts could be phosphorylated in vitro by the catalytic subunit of cAMP-dependent protein kinase (back-phosphorylation). Autoradiography of electrophoresed samples showed several bands. The radioactivity in a band at about 26 kd was reduced in hearts treated with isoproterenol ( Figure 2 ). This could be regarded as indirect evidence that in vivo this protein is phosphorylated via protein kinase A and thus in vitro it was no longer possible to add radioactive phosphate. Next, we investigated whether a protein in the fraction used for inhibitor-1 activity assay was phosphorylated in vivo. Therefore, 12P-labeled hearts were stimulated with isoproterenol, and extracts were subjected to electrophoresis. In autoradiograms of these gels, enhanced radioactivity at several bands was observed (Figure 3 ). Control sodium dodecyl sulfate gels showed two phosphorylated bands at about 23 and about 26 kd. Isoproterenol treatment increased protein phosphorylation of both proteins. In addition, a protein of about 33 kd also appeared ( Figure 3) . Radioactivity at about 26 kd was counted. Figure 3 summarizes the increased phosphorylation of the protein corresponding to this band as observed in five hearts.
To identify which protein is inhibitor-1, the extracts of labeled hearts were electrophoresed and then transferred to nitrocellulose. Nitrocellulose was subjected to autoradiography, and radioactivity at about 26 kd was detectable (Figure 4) nonradioactively labeled extracts from perfused guinea pig hearts (data not shown). It could be argued that several proteins in a one-dimensional gel might migrate with similar M, and hence we might count other proteins in addition to inhibitor-1.
Therefore, inhibitor-1-enriched fractions were immunoprecipitated with anti-inhibitor-1 antiserum. As shown in Figure 5 , it was possible to immunoprecipitate the band at about 26 kd. No immunoprecipitate was detectable with a nonimmune serum (data not shown). Figure 5 (left two lanes) also shows that more radioactive material is precipitated from isoproterenol-treated hearts than from untreated hearts. Finally, the specificity of the immunoprecipitation is indicated in the right lane. The immunoprecipitated material could be largely reduced by preincubating and thereby blocking the antiserum with authentic inhibitor-1. This finding is further evidence for the identity of inhibitor-1 and the band at about 26 kd because it shows directly that the antiserum recognizes a radioactive band. Finally, we studied whether the antiserum is functionally active. As shown in Table 1 , the antiserum clearly precipitated inhibitor-1 activity and therefore presumably also the inhibitor-1 protein from the supernatant to the pellet. This suggests that the material precipitated in Figure 5 has in fact phosphatase inhibitory activity and further supports its identification as inhibitor-1. However, the antiserum did not affect the ability of inhibitor-i to inhibit phosphatase type 1 activity (Table 1) . Thus, it appears that the epitope to which the antibody binds on inhibitor-1 is different from the part of inhibitor-1 that binds to and inhibits the catalytic subunit of phosphatase type 1. As mentioned above, in isoproterenol-stimulated 32P-labeled hearts, radioactivity at about 32 kd was enhanced ( Figure 3 ). It was conceivable that another phosphatase inhibitor called inhibitor-2 might be identical to this protein, because in vitro inhibitor-2 can be phosphorylated with the catalytic subunit of protein kinase A and in the fraction enriched in inhibitor-1 this inhibitor-2 should be copurified, having very similar physical properties. With an antiserum against inhibitor-2 we were able to detect proteins that were recognized in immunoblots from inhibitor-l-enriched fractions. However, the signal did not match with the radioactivity at about 32 kd (data not shown). Hence, the identity of this additional protein remains to be elucidated.
Discussion
The aim of the present study was to investigate the mechanism of the effect of 3-adrenergic stimulation on inhibitor-1 activity in the heart. An enhanced activity of inhibitor-1 has recently been observed in cardiac slices5 and perfused hearts. 6 Similarly, cAMP-increasing agents have been reported to stim- 
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Protocol A: Immune and nonimmune serum were incubated with phosphorylated inhibitor-1 from guinea pig heart (I1-P) for 1 hour at 4C. Then activity of phosphatase was determined in percent of no addition (control) as described in "Materials and Methods." Protocol B: I1-P was incubated with nonimmune and immune serum as above. The current study provides direct evidence for the presence of inhibitor-1 in the heart and its phosphorylation in the presence of cAMP-increasing agents. The method of preparation of the extracts confirms that the protein is heat stable and acid soluble.7 Extracts containing this protein can be phosphorylated in vitro by the catalytic subunit of cAMPdependent protein kinase. This phosphorylation stimulates inhibitory activity of the extracts. In vitro dephosphorylation of extracts by exogenous type 2 phosphatase reduces the inhibitory activity. This pattern is in accord with the published properties of skeletal muscle inhibitor-Li Extracts in vitro phosphorylated (back-phosphorylated) with radioactive ATP show incorporation of radioactivity at several bands. One band is at about 26 kd which is similar to the apparent molecular weight in sodium dodecyl sulfate gel electrophoresis of rabbit skeletal muscle inhibitor-1.7 This finding provided the initial evidence that an inhibitor-l-like protein might be detectable in these extracts. Further, it was thought that this indicated that changes in inhibitor-1 phosphorylation are the result of in vivo phosphorylation of inhibitor-1 by protein kinase A. However, from these experiments, the possibility remained that in vivo protein kinases other than protein kinase A are involved and that the ability of protein kinase A to phosphorylate this band was coincidental. In addition, phosphorylations mediated by cAMP-independent protein kinase might be overlooked by this back-phosphorylation technique.
Hence, extracts from 32P-labeled hearts were prepared for comparison. The phosphorylated protein at about 26 kd is much more prominent with in vivo labeling than with in vitro labeling, which could indicate that it is a very good physiological substrate for protein kinase(s). The protein at about 26 kd interacts with an antiserum raised against rabbit skeletal muscle13 in extracts from both radiolabeled and nonradioactive perfused hearts. In addition, more radioactive material was immunoprecipitated with antiserum from isoproterenol-stimulated than from nonstimulated hearts, and any signal could be greatly attenuated by pretreating the antiserum with authentic inhibitor-1. The identification of the immunoprecipitated material as inhibitor-1 is further supported by the fact that it possesses inhibitor-i-like inhibitory activity on type 1 phosphatase (Table 1) . However, the antiserum did not affect the inhibitory action of inhibitor-1 on type 1 phosphatase. This means that the protein domain on inhibitor-1 that binds and inactivates type 1 phosphatase is different from the domain recognized by the antibody.
These data support the conclusion that the 26-kd protein is identical to inhibitor-1 and hence that inhibitor-1 is present in the heart. This finding is also important in view of the species and tissue differences of expression of inhibitor-1. For instance, in rat and mouse liver no inhibitor-1 could be immunologically detected, whereas it was present in rat heart (tissue difference) and rabbit liver (species differences).14 Its lack of expression in rat liver versus its existence in rabbit liver implies different mechanisms for phosphatase regulation in these two species.
The activity and 32p content of inhibitor-1 is regulated by f3-adrenergic stimulation. Thus, while previous studies have inferred the phosphorylation state of inhibitor-1 from activity measurement,56 we have been able to make direct and independent estimates of this phosphorylation. No direct observations on the 32p content of inhibitor-1 from muscle (skeletal or cardiac) have been reported previously. Such direct evidence is available only in adipose tissue. 15 We cannot exclude the possibility that inhibitor-1 in the heart is also phosphorylated by cAMP-independent protein kinases. There is some evidence that cAMP-independent kinases can phosphorylate inhibitor-i-like proteins in various tissues,15 and it is possible that these cAMP-independent protein kinases might be regulated in an unknown way by ,8-adrenergic stimulation. Alternatively, the phosphorylation state of inhibitor 1 could be by inhibition of a specific inhibitor-1 phosphatase(s). Such an inhibition of a specific phosphatase as a mechanism independent of an activation of protein kinases has been discussed in the literature. 16, 17 We have previously shown that in isoproterenoltreated hearts the increased activity of inhibitor-1 is accompanied by a reduction in phosphatase type 1 activity.6 Hence, isoproterenol would phosphorylate inhibitor-1, which inhibits phosphatase type 1, and this would increase the phosphate content of phosphoproteins in addition to a direct activation of protein kinase A by isoproterenol via a cAMP increase. In this way, the effects of isoproterenol on protein phosphorylation would be amplified. We could not detect an inhibition of type 2 In summary, positive inotropic effects of isoproterenol lead to an increase in cAMP and to an increased activity of protein kinase A. In appropriate fractions of powder from treated hearts, inhibitor-1 activity was increased. Identically prepared fractions from 32P-labeled hearts showed a radioactivity at the apparent molecular weight reported for inhibitor-1. This radioactivity was increased by isoproterenol treatment. This band interacted with an antibody against skeletal muscle inhibitor-1.
We conclude that the physiological effects of cAMP-increasing agents like isoproterenol, which are thought to be brought about by a cascade of events leading to phosphorylation of regulatory proteins, could be amplified by inhibition of phosphatase type 1 mediated via inhibitor-1 phosphorylation.
